The Association between Body Mass Index and Mortality in Breast Cancer Patients Receiving Pembrolizumab

被引：0

作者：

Chiang, Cho-Han ^{[1
]}

Xu, Xiaocao ^{[2
]}

Shahid, Ahmed ^{[2
]}

Song, Junmin ^{[3
]}

Chi, Kuan-Yu ^{[3
]}

Chang, Yu-Cheng ^{[4
]}

Chang, Yu ^{[5
]}

Chiang, Cho-Hung ^{[6
]}

Lin, Shuwen ^{[7
]}

机构：

[1] Harvard Med Sch, Mt Auburn Hosp, Dept Med, Cambridge, MA 02115 USA

[2] Univ Vermont, Dept Med, Div Hematol & Oncol, Med Ctr, Burlington, VT USA

[3] Albert Einstein Coll Med, Jacobi Med Ctr, Dept Med, Bronx, NY USA

[4] Danbury Hosp, Dept Med, Danbury, CT USA

[5] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Surg,Sect Neurosurg, Tainan, Taiwan

[6] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan

[7] Albert Einstein Coll Med, Montefiore Einstein Comprehens Canc Ctr, Dept Oncol, Bronx, NY USA

来源：

ONCOLOGY | 2024年

关键词：

Body mass index; Mortality; Pembrolizumab; Immune checkpoint inhibitor; Breast cancer; IMMUNOTHERAPY; CHEMOTHERAPY; OBESITY;

D O I：

10.1159/000542542

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: A higher body mass index (BMI) has been associated with a better response and overall survival in patients with lung cancer or melanoma receiving immune checkpoint inhibitors (ICIs). Pembrolizumab has been approved for the use of breast cancer, but its relationship with BMI on survival outcomes is unclear. Methods: We conducted a retrospective, propensity score-matched cohort study using the TriNetX Analytics Network database, which contains de-identified data from over 120 participating healthcare institutions. We included all adult female patients with breast cancer who received pembrolizumab. We excluded patients who were prescribed endocrine or human epidermal growth factor receptor 2-targeted therapies. We compared the 1-year all-cause mortality between patients who were overweight or obese (BMI >= 25 kg/m(2)) and those who were normal weight (BMI <25 kg/m(2)). We matched patients on predetermined variables including age, race, breast cancer-directed therapy, cardiovascular and diabetes medications, and underlying comorbidities. Results: We identified 1,628 eligible patients, of whom 1,163 had a BMI >= 25 kg/m(2) and 465 had a BMI <25 kg/m(2). After propensity score matching, 410 patients in each cohort were well balanced for demographics, breast cancer-directed therapy, and underlying comorbidities. The mean ages for patients with BMI >= 25 kg/m(2) and BMI <25 kg/m(2) were 56.7 +/- 14.0 and 56.9 +/- 15.0, respectively. Over a median follow-up of 1 year, 28 and 53 patients died in the BMI >= 25 kg/m(2) and BMI <25 kg/m(2) cohorts, respectively. Patients with BMI >= 25 kg/m(2) had a 49% lower risk of all-cause mortality compared with those with BMI <25 kg/m(2) (hazard ratio, 0.51 [95% CI: 0.33-0.81]). Conclusions: A BMI >= 25 kg/m(2) was associated with a lower all-cause mortality among breast cancer patients receiving pembrolizumab.

引用

页数：5

共 16 条

[1]

Schmid P., Cortes J., Pusztai L., McArthur H., Kummel S., Bergh J., Et al., Pembrolizumab for early triple-negative breast cancer, N Engl J Med., 382, 9, pp. 810-821, (2020)

[2]

Cortes J., Rugo H.S., Cescon D.W., Im S.A., Yusof M.M., Gallardo C., Et al., Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer, N Engl J Med., 387, 3, pp. 217-226, (2022)

[3]

McQuade J.L., Daniel C.R., Hess K.R., Mak C., Wang D.Y., Rai R.R., Et al., Association of bodymass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis, Lancet Oncol., 19, 3, pp. 310-322, (2018)

[4]

Kwok G., Yau T.C., Chiu J.W., Tse E., Kwong Y.L., Pembrolizumab (keytruda), Hum Vaccin Immunother., 12, 11, pp. 2777-2789, (2016)

[5]

Jiang Y., Chen M., Nie H., Yuan Y., PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations, Hum Vaccin Immunother., 15, 5, pp. 1111-1122, (2019)

[6]

Hahn A.W., Menk A.V., Rivadeneira D.B., Augustin R.C., Xu M., Li J., Et al., Obesity is associated with altered tumor metabolism in metastatic melanoma, Clin Cancer Res., 29, 1, pp. 154-164, (2023)

[7]

Wang Z., Aguilar E.G., Luna J.I., Dunai C., Khuat L.T., Le C.T., Et al., Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade, Nat Med., 25, 1, pp. 141-151, (2019)

[8]

Palchuk M.B., London J.W., Perez-Rey D., Drebert Z.J., Winer-Jones J.P., Thompson C.N., Et al., A global federated real-world data and analytics platform for research, JAMIA Open., 6, 2, (2023)

[9]

Zhang Z., Kim H.J., Lonjon G., Zhu Y., Balance diagnostics after propensity score matching, Ann Transl Med., 7, 1, (2019)

[10]

AlZaim I., Hammoud S.H., Al-Koussa H., Ghazi A., Eid A.H., El-Yazbi A.F., Adipose tissue immunomodulation: a novel therapeutic approach in cardiovascular and metabolic diseases, Front Cardiovasc Med., 7, (2020)

← 1 2 →